Rocket Pharmaceuticals Inc (RCKT)
Drugs • Health Care
August 03, 2026 Rocket Pharmaceuticals Reports Positive Clinical Safety Update for RP-A501 in Danon Disease Rocket Pharmaceuticals has released a positive clinical safety update for RP-A501, a gene therapy for Danon disease, showing no significant safety concerns in initial patients. The company is engaging with the FDA to discuss expanding its Phase 2 trial, with further updates expected in late 2026.
June 12, 2026 Rocket Pharmaceuticals Secures $180 Million from Sale of Rare Pediatric Disease Priority Review Voucher Rocket Pharmaceuticals sold its Rare Pediatric Disease Priority Review Voucher for $180 million, significantly increasing its cash reserves to approximately $322.6 million. This strategic move supports the company's commitment to advancing gene therapies for rare diseases and sustaining operations through mid-2028.
May 28, 2026 Rocket Pharmaceuticals Inc. to Engage Investors in Upcoming Conferences Rocket Pharmaceuticals will participate in the Jefferies and Goldman Sachs healthcare conferences in June 2026, offering insights into their gene therapies for rare genetic disorders. CEO Dr. Gaurav Shah will lead discussions, enhancing investor relations and showcasing the company's strategic advancements.
May 07, 2026 Rocket Pharmaceuticals Reports Strong Q1 2026 Financial Results and Strategic Advances in Gene Therapy Rocket Pharmaceuticals announced strong Q1 2026 financial results, showcasing advancements in its gene therapy pipeline, including the reinitiation of studies for Danon disease and the accelerated approval of KRESLADI™. The company's financial position was bolstered by a $180 million regulatory voucher monetization, extending its cash runway into 2028.
April 28, 2026 Rocket Pharmaceuticals Strengthens Financial Position with $180 Million PRV Sale Rocket Pharmaceuticals has sold its Rare Pediatric Disease Priority Review Voucher for $180 million, enhancing its financial position and extending its cash runway. This strategic move will support the advancement of its cardiovascular gene therapy pipeline, addressing serious rare conditions.
February 26, 2026 Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results Rocket Pharmaceuticals announced its Q4 and full year 2025 financial results, highlighting advancements in cardiovascular gene therapies. The company reported a strategic focus on clinical trials, reduced R&D expenses, and positive cash projections for future operations.
February 26, 2026 Rocket Pharmaceuticals Inc. Reports on 2025 Financial Performance Rocket Pharmaceuticals reported a net loss of $223.1 million for 2025, showing improvement from the previous year. The company is focusing on gene therapies for rare cardiovascular diseases while undergoing a significant corporate reorganization to enhance operational efficiency amidst ongoing regulatory challenges.
February 23, 2026 Rocket Pharmaceuticals to Engage Investors at Major Conferences Rocket Pharmaceuticals is set to engage investors at the TD Cowen and Leerink Partners conferences in March 2026. CEO Dr. Gaurav Shah will share insights on the company's innovative genetic therapies addressing rare diseases, reflecting its commitment to advancing investor relations.
January 05, 2026 Rocket Pharmaceuticals Set to Showcase Innovations at J.P. Morgan Healthcare Conference Rocket Pharmaceuticals will present its advancements in genetic therapies for rare disorders at the J.P. Morgan Healthcare Conference. CEO Gaurav Shah will discuss the company's pipeline and future strategies, highlighting their commitment to transforming patient care.
November 25, 2025 Rocket Pharmaceuticals Set to Showcase Innovations at Evercore Healthcare Conference Rocket Pharmaceuticals will present its advancements in genetic therapies at the Evercore Healthcare Conference on December 2, 2025. CEO Dr. Gaurav Shah will discuss the company's strategic goals and ongoing projects aimed at treating rare diseases. This participation highlights Rocket's commitment to innovation in the biotechnology sector.
November 06, 2025 Rocket Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Milestones Rocket Pharmaceuticals reported its Q3 2025 results, highlighting progress in its gene therapy pipeline, including the resumption of pivotal trials for Danon disease. The company also announced new leadership appointments and maintained a strong financial position to support future growth in treating rare disorders.
November 06, 2025 Rocket Pharmaceuticals Inc. Reports Q3 2025 Financial Results: Strategic Realignment and Clinical Advances Rocket Pharmaceuticals Inc. has reported a reduced net loss in Q3 2025, driven by strategic realignment and prioritization of its gene therapy pipeline. The company aims to enhance operational efficiency while advancing innovative treatments for rare diseases.
October 10, 2025 Rocket Pharmaceuticals Expands Executive Team with Inducement Equity Awards Rocket Pharmaceuticals has appointed Dr. Syed Rizvi as Chief Medical Officer, granting him substantial equity awards to reinforce leadership. This move aligns with their commitment to developing innovative therapies for rare diseases and strengthens their operational capabilities as they advance their clinical pipeline.
August 07, 2025 Rocket Pharmaceuticals Inc. Reports Q2 2025 Financial Results: Strategic Reorganization and Clinical Progress Amidst Challenges Rocket Pharmaceuticals reported a net income loss of $68.91 million in Q2 2025, showing slight improvement year-over-year. The company is undergoing a strategic reorganization to enhance operational efficiency and focus on key therapies while facing regulatory challenges.
May 15, 2025 Rocket Pharmaceuticals Showcases Promising Early Results for Gene Therapy RP-A601 Rocket Pharmaceuticals revealed promising preliminary results for its gene therapy RP-A601 at the ASGCT meeting. The Phase 1 trial indicated a positive safety profile and significant improvements in heart function and quality of life for patients with PKP2-ACM.
May 09, 2025 Rocket Pharmaceuticals Announces Significant Data Presentation at ASGCT Annual Meeting Rocket Pharmaceuticals will present critical findings from its Phase 1 clinical trial of RP-A601 for PKP2-Arrhythmogenic Cardiomyopathy at ASGCT 2025. This innovative gene therapy could significantly improve outcomes for patients with this severe cardiac condition.
May 08, 2025 Rocket Pharmaceuticals Inc. Reports 2025 Q1 Financial Results: Focus on Gene Therapy Innovations Rocket Pharmaceuticals Inc. released its Q1 2025 financial results, revealing a net loss of $61.3 million as it focuses on gene therapy innovations. Despite financial challenges, the company is advancing clinical programs and maintaining strong R&D investments, setting the stage for future growth.
May 08, 2025 Rocket Pharmaceuticals Reports Strong Q1 2025 Financial Results and Progress in Genetic Therapies Rocket Pharmaceuticals reports strong Q1 2025 financials, highlighting progress in its gene therapy pipeline. The company emphasizes its commitment to addressing rare diseases and enhancing shareholder value with promising clinical studies and new leadership.
April 03, 2025 Rocket Pharmaceuticals Set to Showcase Innovations at Needham Virtual Healthcare Conference Rocket Pharmaceuticals will showcase its advancements in genetic therapies at the Needham Virtual Healthcare Conference on April 8, 2025. CEO Dr. Gaurav Shah will lead a fireside chat, discussing the company's innovative pipeline aimed at rare genetic disorders. A webcast will be available for live and archived access.
March 17, 2025 SWOT Analysis of Rocket Pharmaceuticals Inc. in 2025 This SWOT analysis of Rocket Pharmaceuticals Inc. in 2025 outlines the company's strengths in gene therapies, its financial weaknesses, market opportunities, and competitive threats. It emphasizes the need for strategic focus to ensure future success in the evolving biotech landscape.
February 27, 2025 Rocket Pharmaceuticals Inc. Reports 2024 Annual Financial Results Rocket Pharmaceuticals Inc. reported significant net losses of $258.7 million in 2024 amid heavy R&D investments. The company continues to advance its gene therapy pipeline, targeting rare diseases while navigating financial challenges.
November 07, 2024 Rocket Pharmaceuticals Inc. Reports Q3 2024 Financial Results: A Strategic Positioning for Gene Therapy Breakthroughs Rocket Pharmaceuticals Inc. reported a net loss of $66.71 million in Q3 2024, alongside significant advancements in its gene therapy pipeline. The company continues to attract investor interest despite current financial challenges, showcasing robust liquidity and strategic positioning for future breakthroughs.
August 06, 2024 Rocket Pharmaceuticals Inc. Reports Q2 2024 Financial Results: A Mixed Bag Amidst Regulatory Challenges Rocket Pharmaceuticals Inc. revealed its Q2 2024 financial results, showcasing a net loss increase amid regulatory hurdles. Despite these challenges, the company advances its gene therapy pipeline and maintains sufficient cash reserves for future growth.
May 07, 2024 Rocket Pharmaceuticals Inc. Releases Q1 2024 Financial Report: Progress Amidst Challenges Rocket Pharmaceuticals reported a net loss of $62.1 million for Q1 2024, increasing from the previous year. Despite financial challenges, the company is advancing its gene therapy pipeline and enhancing its leadership team to drive future growth.